Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NF-κB represses retinoic acid receptor–mediated GPRC5A transactivation in lung epithelial cells to promote neoplasia
Hongyong Song, Xiaofeng Ye, Yueling Liao, Siwei Zhang, Dongliang Xu, Shuangshuang Zhong, Bo Jing, Tong Wang, Beibei Sun, Jianhua Xu, Wenzheng Guo, Kaimi Li, Min Hu, Yanbin Kuang, Jing Ling, Tuo Zhang, Yadi Wu, Jing Du, Feng Yao, Y. Eugene Chin, Qi Wang, Binhua P. Zhou, Jiong Deng
Hongyong Song, Xiaofeng Ye, Yueling Liao, Siwei Zhang, Dongliang Xu, Shuangshuang Zhong, Bo Jing, Tong Wang, Beibei Sun, Jianhua Xu, Wenzheng Guo, Kaimi Li, Min Hu, Yanbin Kuang, Jing Ling, Tuo Zhang, Yadi Wu, Jing Du, Feng Yao, Y. Eugene Chin, Qi Wang, Binhua P. Zhou, Jiong Deng
View: Text | PDF | Corrigendum
Research Article Oncology

NF-κB represses retinoic acid receptor–mediated GPRC5A transactivation in lung epithelial cells to promote neoplasia

  • Text
  • PDF
Abstract

Chronic inflammation is associated with lung tumorigenesis, in which NF-κB–mediated epigenetic regulation plays a critical role. Lung tumor suppressor G protein–coupled receptor, family C, member 5A (GPRC5A), is repressed in most non–small cell lung cancer (NSCLC); however, the mechanisms remain unclear. Here, we show that NF-κB acts as a transcriptional repressor in suppression of GPRC5A. NF-κB induced GPRC5A repression both in vitro and in vivo. Intriguingly, transactivation of NF-κB downstream targets was not required, but the transactivation domain of RelA/p65 was required for GPRC5A repression. NF-κB did not bind to any potential cis-element in the GPRC5A promoter. Instead, p65 was complexed with retinoic acid receptor α/β (RARα/β) and recruited to the RA response element site at the GPRC5A promoter, resulting in disrupted RNA polymerase II complexing and suppressed transcription. Notably, phosphorylation on serine 276 of p65 was required for interaction with RARα/β and repression of GPRC5A. Moreover, NF-κB–mediated epigenetic repression was through suppression of acetylated histone H3K9 (H3K9ac), but not DNA methylation of the CpG islands, at the GPRC5A promoter. Consistently, a histone deacetylase inhibitor, but not DNA methylation inhibitor, restored GPRC5A expression in NSCLC cells. Thus, NF-κB induces transcriptional repression of GPRC5A via a complex with RARα/β and mediates epigenetic repression via suppression of H3K9ac.

Authors

Hongyong Song, Xiaofeng Ye, Yueling Liao, Siwei Zhang, Dongliang Xu, Shuangshuang Zhong, Bo Jing, Tong Wang, Beibei Sun, Jianhua Xu, Wenzheng Guo, Kaimi Li, Min Hu, Yanbin Kuang, Jing Ling, Tuo Zhang, Yadi Wu, Jing Du, Feng Yao, Y. Eugene Chin, Qi Wang, Binhua P. Zhou, Jiong Deng

×

Figure 7

NF-κB–mediated GPRC5A suppression is associated with epigenetic alteration.

Options: View larger image (or click on image) Download as PowerPoint
NF-κB–mediated GPRC5A suppression is associated with epigenetic alterati...
(A) GPRC5A protein expression level in multiple human NSCLC cell lines and normal human bronchial epithelial cell line (16HBE) was analyzed by Western blotting. (B) Calu-1 cells treated with or without TNF-α (10 ng/mL) for 12 hours. Binding of RNA polymerase II and the histone modification at the GPRC5A promoter were analyzed by ChIP using specific antibodies. (C and D) Calu-1 cells with inducible expression of WT and serine 276A mutant p65 were treated with doxycycline (300 ng/mL) for 12 hours; the change of RNA polymerase II binding (C) and histone modification (H3K9ac) at the GPRC5A promoter (D) were analyzed by ChIP. Input as positive control and normal IgG (N IgG) as negative control. (E–H) A549, H1975, and Calu-1 cells were treated with 5-Aza-dc (1 μM, 4 days) or SAHA (2.5 μM, 24 hours) individually or in combination; GPRC5A protein (E–G) and mRNA levels (H) were analyzed via Western blotting and qPCR. Data are presented as the mean ± SD. (I) Calu-1 cells were treated with or without SAHA (2.5 μM) for 12 hours; RNA polymerase II binding at the GPRC5A promoter was analyzed by ChIP. (J) Normal human bronchial epithelial cell line (16HBE) and multiple human NSCLC cell lines were treated with or without SAHA (2.5 μM, 24 hours); GPRC5A protein levels were analyzed by Western blotting. (K) Calu-1 cells were pretreated with DMSO (as vehicle control), 5-Aza-dc (1 μM, 3 days) or SAHA (2.5 μM, 3 hours) followed by TNF-α (10 ng/mL) treatment for an additional 24 hours. GPRC5A protein levels were analyzed by Western blotting. All data are presented as mean ± SD from 3 independent experiments with duplicates and analyzed by 2-tailed Student’s t test, **P < 0.01; ***P < 0.001. H3K9ac, acetylated histone H3K9.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts